• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

塞内加尔2011年至2020年纯合子镰状细胞病相关死亡率

Homozygous sickle cell disease related mortality in Senegal (2011-2020).

作者信息

Seck Moussa, Ba Oumou, Faye Blaise Felix, Touré Sokhna Aissatou, Guèye Youssou Bamar, Dieng Nata, Sall Abibatou, Gadji Macoura, Touré Awa Oumar, Diop Saliou

机构信息

Hematology Department Cheikh Anta Diop University Dakar Senegal.

National Blood Transfusion Center Clinical Hematology Dakar Senegal.

出版信息

EJHaem. 2021 Oct 4;2(4):711-715. doi: 10.1002/jha2.273. eCollection 2021 Nov.

DOI:10.1002/jha2.273
PMID:35845188
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9176000/
Abstract

Homozygous sickle cell disease (HSCD) is characterized by multiorgan morbidity and an increased risk of early death. We aim to describe the mortality rate, causes, and risk factors of death in HSCD between 2011 and 2020. We conducted a retrospective study with a duration of 10 years in the cohort of 2348 HSCD patients. The mortality rate was determined by reporting the number of deaths to the total number of patients followed in the year. Sociodemographic, clinical, biological data and causes of death were studied. Death risk factors were determined by a bivariate analysis comparing deceased and living HSCD patients. The mean age of death was 26 years (3-52). The sex ratio was 1.2. The mortality rate was 2.76%. The death rate was high in 2011 (3.2%) and low in 2020 (0.17%). We observed a significant reduction of mortality of 94.6%. Most of the common causes of death were acute anemia (40%), acute chest syndrome (24.6%), and infections (20%). Risk factors of death were age, vaso-occlusive crises ≥3, acute chest syndrome, blood transfusion, and chronic complications. Mortality among HSCD has significantly decreased over the past 10 years in Senegal, and the main causes of death were acute anemia, acute chest syndrome, and infections.

摘要

纯合子镰状细胞病(HSCD)的特征是多器官发病以及早期死亡风险增加。我们旨在描述2011年至2020年间HSCD的死亡率、死亡原因和死亡风险因素。我们对2348例HSCD患者队列进行了为期10年的回顾性研究。死亡率通过报告当年死亡人数与随访患者总数来确定。研究了社会人口统计学、临床、生物学数据及死亡原因。通过对已故和在世的HSCD患者进行双变量分析来确定死亡风险因素。平均死亡年龄为26岁(3至52岁)。男女比例为1.2。死亡率为2.76%。2011年死亡率较高(3.2%),2020年较低(0.17%)。我们观察到死亡率显著降低了94.6%。大多数常见死亡原因是急性贫血(40%)、急性胸综合征(24.6%)和感染(20%)。死亡风险因素包括年龄、血管闭塞性危机≥3次、急性胸综合征、输血和慢性并发症。在塞内加尔,过去10年中HSCD的死亡率显著下降,主要死亡原因是急性贫血、急性胸综合征和感染。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6ba/9176000/49a8db4042c0/JHA2-2-711-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6ba/9176000/49a8db4042c0/JHA2-2-711-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6ba/9176000/49a8db4042c0/JHA2-2-711-g001.jpg

相似文献

1
Homozygous sickle cell disease related mortality in Senegal (2011-2020).塞内加尔2011年至2020年纯合子镰状细胞病相关死亡率
EJHaem. 2021 Oct 4;2(4):711-715. doi: 10.1002/jha2.273. eCollection 2021 Nov.
2
Preoperative blood transfusions for sickle cell disease.镰状细胞病的术前输血
Cochrane Database Syst Rev. 2020 Jul 2;7(7):CD003149. doi: 10.1002/14651858.CD003149.pub4.
3
Preoperative blood transfusions for sickle cell disease.镰状细胞病的术前输血
Cochrane Database Syst Rev. 2016 Apr 6;4(4):CD003149. doi: 10.1002/14651858.CD003149.pub3.
4
Hemorheological risk factors of acute chest syndrome and painful vaso-occlusive crisis in children with sickle cell disease.镰状细胞病患儿急性胸部综合征和疼痛性血管阻塞危象的血液流变学危险因素。
Haematologica. 2012 Nov;97(11):1641-7. doi: 10.3324/haematol.2012.066670. Epub 2012 Jun 11.
5
Homozygous Sickle Cell Disease after Age of 40: Follow-Up of a Cohort of 209 Patients in Senegal, West Africa.40岁后纯合子镰状细胞病:西非塞内加尔209例患者队列的随访
Adv Hematol. 2024 Feb 6;2024:7501577. doi: 10.1155/2024/7501577. eCollection 2024.
6
The risk of acute events among patients with sickle cell disease in relation to early or late initiation of care at a specialist center: evidence from a retrospective cohort study.镰状细胞病患者在专科中心早启动或晚启动治疗的急性事件风险:一项回顾性队列研究的证据
BMC Pediatr. 2020 Aug 8;20(1):373. doi: 10.1186/s12887-020-02270-y.
7
New results in clinical severity of homozygous sickle cell anemia, in Dakar, Senegal.塞内加尔达喀尔纯合子镰状细胞贫血临床严重程度的新结果。
Hematol Cell Ther. 1999 Nov;41(5):217-21. doi: 10.1007/s00282-999-0217-1.
8
Mortality in children, adolescents and adults with sickle cell anemia in Rio de Janeiro, Brazil.巴西里约热内卢镰状细胞贫血儿童、青少年及成人的死亡率
Hematol Transfus Cell Ther. 2018 Jan-Mar;40(1):37-42. doi: 10.1016/j.bjhh.2017.09.006. Epub 2017 Dec 6.
9
Clinical Profiles of Children With Sickle Cell Anaemia Presenting With Acute Clinical Events: A Single-Center Study.患有镰状细胞贫血且出现急性临床事件的儿童的临床概况:一项单中心研究。
Cureus. 2023 May 14;15(5):e39008. doi: 10.7759/cureus.39008. eCollection 2023 May.
10
Evaluation of transfusion practices in sickle cell disease in Senegal: cohort study of 1078 patients with sickle cell disease.塞内加尔镰状细胞病输血实践的评估:对1078例镰状细胞病患者的队列研究。
Med Sante Trop. 2017 Nov 1;27(4):402-406. doi: 10.1684/mst.2017.0744.

引用本文的文献

1
Prevalence and Predictive Factors of Sickle Cell Emergencies Readmission in the Clinical Hematology Department of Dakar, Senegal.塞内加尔达喀尔临床血液科镰状细胞病紧急情况再入院的患病率及预测因素
Anemia. 2024 Nov 21;2024:7143716. doi: 10.1155/anem/7143716. eCollection 2024.
2
Beyond pulmonary embolism: Alternative diagnosis and incidental findings on CT pulmonary angiography in sickle cell disease.超越肺栓塞:镰状细胞病 CT 肺动脉造影的其他诊断和偶然发现。
Emerg Radiol. 2024 Jun;31(3):321-330. doi: 10.1007/s10140-024-02229-x. Epub 2024 Apr 15.
3
Homozygous Sickle Cell Disease after Age of 40: Follow-Up of a Cohort of 209 Patients in Senegal, West Africa.

本文引用的文献

1
Transfusion and sickle cell anemia in Africa.输血与非洲镰状细胞贫血。
Transfus Clin Biol. 2021 May;28(2):143-145. doi: 10.1016/j.tracli.2021.01.013. Epub 2021 Jan 27.
2
Low hemoglobin increases risk for cerebrovascular disease, kidney disease, pulmonary vasculopathy, and mortality in sickle cell disease: A systematic literature review and meta-analysis.低血红蛋白水平增加镰状细胞病患者发生脑血管疾病、肾脏疾病、肺血管病变和死亡的风险:系统文献回顾和荟萃分析。
PLoS One. 2020 Apr 3;15(4):e0229959. doi: 10.1371/journal.pone.0229959. eCollection 2020.
3
Blood transfusions for treating acute chest syndrome in people with sickle cell disease.
40岁后纯合子镰状细胞病:西非塞内加尔209例患者队列的随访
Adv Hematol. 2024 Feb 6;2024:7501577. doi: 10.1155/2024/7501577. eCollection 2024.
4
Enuresis and overactive bladder in sickle cell patients: a narrative review of the literature.镰状细胞病患者的遗尿和膀胱过度活动症:文献综述的叙述
World J Urol. 2023 Apr;41(4):953-962. doi: 10.1007/s00345-023-04288-0. Epub 2023 Jan 20.
输血治疗镰状细胞病患者的急性胸部综合征。
Cochrane Database Syst Rev. 2020 Jan 16;1(1):CD007843. doi: 10.1002/14651858.CD007843.pub4.
4
The morbidity and mortality of end stage renal disease in sickle cell disease.镰状细胞病终末期肾病的发病率和死亡率。
Am J Hematol. 2019 May;94(5):E138-E141. doi: 10.1002/ajh.25439. Epub 2019 Mar 1.
5
Clustering of end-organ disease and earlier mortality in adults with sickle cell disease: A retrospective-prospective cohort study.镰状细胞病成人终末器官疾病聚类与早期死亡率:一项回顾性前瞻性队列研究。
Am J Hematol. 2018 Sep;93(9):1153-1160. doi: 10.1002/ajh.25202. Epub 2018 Jul 30.
6
Sickle cell disease.镰状细胞病。
Nat Rev Dis Primers. 2018 Mar 15;4:18010. doi: 10.1038/nrdp.2018.10.
7
Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease.预防性使用抗生素预防镰状细胞病患儿的肺炎球菌感染。
Cochrane Database Syst Rev. 2017 Oct 10;10(10):CD003427. doi: 10.1002/14651858.CD003427.pub4.
8
Hematopoietic stem cell transplantation for sickle cell disease: The changing landscape.镰状细胞病的造血干细胞移植:不断变化的形势。
Hematol Oncol Stem Cell Ther. 2017 Dec;10(4):259-266. doi: 10.1016/j.hemonc.2017.05.008. Epub 2017 Jun 15.
9
Hydroxyurea (hydroxycarbamide) for sickle cell disease.羟基脲(羟基脲素)用于镰状细胞病。
Cochrane Database Syst Rev. 2017 Apr 20;4(4):CD002202. doi: 10.1002/14651858.CD002202.pub2.
10
Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe.镰状细胞病成年患者死亡的危险因素:北美和欧洲研究的荟萃分析
Haematologica. 2017 Apr;102(4):626-636. doi: 10.3324/haematol.2016.153791. Epub 2017 Jan 19.